Reports

Drug name	NICE TAs	Comments
Sirolimus solution#amber	TA85 - Immunosuppressive therapy for renal transplantation in adults	Post-transplant pre 2015
Sirolimus tablets	TA85 - Immunosuppressive therapy for renal transplantation in adults	New post-transplant
Sirolimus tablets#amber	TA85 - Immunosuppressive therapy for renal transplantation in adults	Post-transplant pre 2015
Sodium zirconium cyclosilicate (Lokelma®)	TA599 - Sodium zirconium cyclosilicate for treating hyperkalaemia	Amber specialist initiation with RICaD
Solriamfetol (Sunosi®)	TA 758 - Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy
Somatrogon (Ngenla®)	TA863 - Somatrogon for treating growth disturbance in children and young people aged 3 years and over
Somatropin injection	TA188 - Human growth hormone (somatropin) for the treatment of growth failure in children (review) TA64 - Growth hormone deficiency (adults) - human growth hormone
Sorafenib tablets	TA178 - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma TA474 - Sorafenib for treating advanced hepatocellular carcinoma	National CDF list. Negative outcome - CDF funded.
Sotrovimab (Xevudy®)	TA878 - Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Streptokinase injection	TA52 - Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction	Hospital use only

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports